MedPath

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Phase 3
Terminated
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Registration Number
NCT05442775
Lead Sponsor
Cytokinetics
Brief Summary

The purpose of this study is to assess the long-term safety and tolerability of reldesemtiv in patients with ALS who have successfully completed dosing in the Phase 3 clinical trial, CY 5031 (also known as COURAGE-ALS)

Detailed Description

CY 5032 is an open-label extension (OLE) study of the selective fast skeletal muscle troponin activator, reldesemtiv, in patients with ALS who finished dosing (through Week 48) in CY 5031 (COURAGE-ALS). Approximately 400 patients from the sites that participated in CY 5031 are expected to be enrolled in the open-label extension, CY 5032.

Following enrollment, patients will continue dosing with reldesemtiv, 300 mg twice a day for a 600 mg total daily dose (TDD) for a period of 48 weeks.

At the end of 48 weeks, patients may transition to a reldesemtiv Managed Access Program (MAP) if the treating physician agrees to participate in the program.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
71
Inclusion Criteria
  • Able to comprehend and willing to sign an ICF and willing to comply with all study procedures and restrictions for the duration specified in the Schedule of Activities. If non-written consent is given, a Legal Designee of the patient must sign the ICF form.
  • Completed dosing in CY 5031
Exclusion Criteria
  • Has taken investigational study drug (other than reldesemtiv) prior to dosing, within 30 days or five half-lives of the prior agent, whichever is greater
  • Presence on Day 1 of any medically significant cardiac, pulmonary, gastrointestinal, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or efficacy data.
  • Use of a strong cytochrome P450 (CYP) 3A4 inhibitor within 7 days prior to first dose of reldesemtiv in CY 5032 or a strong CYP3A4 inducer within 14 days prior to first dose of reldesemtiv in CY 5032
  • Use of a medication that is an OCT1/OCT2 substrate within 7 days prior to first dose of reldesemtiv in CY 5032
  • Currently participating in another trial, managed access program, open label extension, early access program, or through the right to try act is receiving an investigational drug or received an investigational drug or device within 30 days (or 5 half-lives for drugs, whichever is longer) prior to Day 1. Patients also cannot be taking outside of a clinical trial certain investigational drugs (which includes drugs, supplements, and nutraceuticals) that are currently being studied or have been studied for the treatment of ALS.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Reldesemtiv 300 mg twice dailyReldesemtivPatients in this arm take 1 reldesemtiv 300 mg oral tablet twice a day for a 600 mg total daily dose (TDD). Participants who had been down titrated during the parent trail take 150 mg by mouth twice a day.
Primary Outcome Measures
NameTimeMethod
Long-term Safety and TolerabilityBaseline to Week 34 (time the study was terminated prematurely)

Incidence of treatment-emergent adverse events

Secondary Outcome Measures
NameTimeMethod
Long-term Effect of Reldesemtiv on ALSFRS-R Functional OutcomesBaseline to Week 32 (last timepoint before study was terminated prematurely)

Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total scores. ALSFRS-R total score range is from 0 to 48. A score of 48 reflects normal function.

Trial Locations

Locations (41)

University of California Irvine - ALS & Neuromuscular Center

🇺🇸

Orange, California, United States

Mayo Clinic Jacksonville

🇺🇸

Jacksonville, Florida, United States

Michigan Medicine

🇺🇸

Ann Arbor, Michigan, United States

Hospital for Special Surgery

🇺🇸

New York, New York, United States

Texas Neurology, P.A.

🇺🇸

Dallas, Texas, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

Atrium Health Neuroscience Institute

🇺🇸

Charlotte, North Carolina, United States

SUNY Upstate Medical University Institute for Human Performance

🇺🇸

Syracuse, New York, United States

The Perron Institute

🇦🇺

Nedlands, Australia

Concord Repatriation General Hospital

🇦🇺

Concord, New South Wales, Australia

Royal Brisbane and Women's Hospital, Neurology Department

🇦🇺

Herston, Queensland, Australia

Uz Leuven Gasthuisberg Department of Neurology

🇧🇪

Leuven, Belgium

Sunnybrook Health Sciences Centre

🇨🇦

Toronto, Ontario, Canada

Ottawa Hospital Research Institute

🇨🇦

Ottawa, Ontario, Canada

CHU de Quebec-Universite Laval

🇨🇦

Quebec, Canada

UMC Utrecht Department of Neurology, ALS Center

🇳🇱

Utrecht, Netherlands

Hospital San Rafael

🇪🇸

Madrid, Spain

Hospital Universitario y Politecnico La Fe

🇪🇸

Valencia, Spain

Studieenheten, Akademiskt Specialistcentrum

🇸🇪

Stockholm, Sweden

The University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

University of Alberta

🇨🇦

Edmonton, Alberta, Canada

George Washington Medical Faculty Associates

🇺🇸

Washington, District of Columbia, United States

Montreal Neurological Institute and Hospital

🇨🇦

Montréal, Quebec, Canada

RSCI Education and Research Center Beaumount Hospital

🇮🇪

Dublin, Ireland

McMaster University

🇨🇦

Hamilton, Ontario, Canada

Neurology Associates

🇺🇸

Lincoln, Nebraska, United States

University of Calgary - Heritage Medical Research Clinic

🇨🇦

Calgary, Alberta, Canada

University of Saskatchewan

🇨🇦

Saskatoon, Saskatchewan, Canada

University of Florida

🇺🇸

Jacksonville, Florida, United States

Stan Cassidy Centre for Rehabilitation

🇨🇦

Fredericton, New Brunswick, Canada

IRCCS Istituto Auxologico Italiano Ospedale San Luca U.O. Neurologia e Stroke Unit

🇮🇹

Milan, Italy

AOU Citta della Salute e della Scienza di Torino Universita degli Studi di Torino P.O. Mollinette - Dipartimento de Neuroscienze "Rita Levi Montalcini"

🇮🇹

Torino, Italy

St. Joseph's Hospital & Medical Center - Barrow Neurological Institute

🇺🇸

Phoenix, Arizona, United States

California Pacific Medical Center - Forbes Norris MDA/ALS Research Center

🇺🇸

San Francisco, California, United States

Indiana University IU Health Neuroscience Center

🇺🇸

Indianapolis, Indiana, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Froedtert Hospital - Department of Neurology

🇺🇸

Milwaukee, Wisconsin, United States

University of Colorado Hospital Anschutz Outpatient Pavilion

🇺🇸

Aurora, Colorado, United States

University of South Florida - Carol and Frank Morsani Center for Advanced Health Care

🇺🇸

Tampa, Florida, United States

Virginia Commonwealth University

🇺🇸

Henrico, Virginia, United States

Johns Hopkins Outpatient Center

🇺🇸

Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath